This CPD presents the updated diagnostic and treatment recommendations around Mild Cognitive Impairment (MCI), Vascular Cognitive Impairment (VCI), probable/possible Alzheimer’s Disease (AD), Rapidly Progressing Dementia (RPD,) and Early Onset Dementia (EOD). It also offers insight into areas such as neuroimaging and liquid biomarkers, while offering advice on how to discuss with your patients the recommendations around the use of these in Canada.
Upon completion of this CME, learners will be able to:
- Demonstrate how to use the different criteria for the diagnosis of dementia, Mild Cognitive Impairment (MCI), Alzheimer’s Disease ( AD) and Vascular Cognitive Impairment (VCI) into their assessment of cognitive impairment;
- Interpret current recommendations for medication use in the treatment of dementia, including (but not limited to) cholinesterase inhibitors, antipsychotics, and anti-depressants;
- Define community and culturally appropriate resources which will support patients and their care partners;
- Explain how to apply treatment and management strategies in their practice for dementia risk factors;
- Identify when it is appropriate to engage a specialist referral for dementia;
- Discuss effective communication techniques to use with patients and their care partners regarding the recommended appropriate use of neuroimaging and liquid biomarkers.
Accreditation for this course expires on
Sunday, January 19, 2014
As an accredited provider, Professional Development & Conferencing Services, Memorial University of Newfoundland designates this continuing medical education (CME)/continuing professional development (CPD) activity for:
- Carl Fournier, MD, MCFP
- Graeme Bethune, MD, CCFP, FCFP, CDE
- Lydia Hatcher, MD, CCFP, FCFP, CAPM